Cancer stem cells in head and neck cancer: A mini review

Cellular and Molecular Biology

Volumn 61, Issue 6, 2015, Pages 39-43

  Galbiatti Dias, Ana Lívia Silva ^a   Pavarino, E C ^a   Kawasaki Oyama, R S ^a   Maniglia, J V ^a   Maniglia, E J V ^a   Goloni Bertollo, E M ^a  

^a FAMERP Sao Jose do Rio Preto Medical School   (Brazil)

Author keywords

Biomarkers; Cancer stem cells; Head and neck neoplasms

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD133 ANTIGEN; HERMES ANTIGEN; TUMOR MARKER; ANTINEOPLASTIC AGENT; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE;

ARTICLE; CANCER PROGNOSIS; CANCER STEM CELL; HEAD AND NECK CANCER; HUMAN; TREATMENT PLANNING; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HEAD AND NECK NEOPLASMS; HIGH THROUGHPUT SCREENING; METABOLISM; PATHOLOGY;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DRUG RESISTANCE, NEOPLASM; GLYCOPROTEINS; HEAD AND NECK NEOPLASMS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NEOPLASTIC STEM CELLS; PEPTIDES;

EID: 84962184047     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: 10.14715/cmb/2015.61.6.7     Document Type: Article

References (75)

1. Scully, C., Bagan, J., Oral squamous cell carcinoma overview. Oral Oncology 2009, 45: 301-308. doi: 10.1111/j.1601-0825.2009.01563.x
2. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J. Clin. 2011, 61: 69-90.
3. Bray, F., Jemal, A., Grey, N., Ferlay, J., Forman, D., Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol 2012; 13(8):790-801. doi: 10.1016/S1470-2045(12)70211-5.
4. Foundation OC. Oral Cancer Facts, 2014. Available in: http://oralcancerfoundation.org/facts/index.htm. Asia Pac J Clin Oncol. 2014 Aug 17. doi: 10.1111/ajco.12261.
5. Choi, S., Myers, J.N., Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res 2008, 87(1):14-32. Review. Erratum J Dent Res 2008, 87:189-91.
6. Marcu, L.G., Yeoh, E., A review of risk factors and genetic alterations in head and neck carcinogenesis and implications for current and future approaches to treatment. J Cancer Res Clin Oncol. 2009, 135:1303-14. doi: 10.1007/s00432-009-0648-7
7. Hashibe, M., Brennan, P., Chuang, S.C., Boccia, S., Castellsague, X., Chen, C., Curado, M.P., et al., Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009; 18: 541-50. doi: 10.1158/1055-9965.EPI-08-0347
8. Galbiatti, A,L, Ruiz, M.T., Biselli-Chicote, P.M., Raposo, L.S., Maniglia, J.V., Pavarino-Bertelli, E.C., Goloni-Bertollo, E.M. 5-Methyltetrahydrofolate-homocysteine methyltransferase gene polymorphism (MTR) and risk of head and neck cancer. Braz J Med Biol Res 2010; 43:445-50.
9. Chuang, S.C, Jenab, M., Heck, J.E., Bosetti, C., Talamini, R., Matsuo, K., Diet and the risk of head and neck cancer: a pooled analysis in the INHANCE consortium. Cancer Causes Control. 2012; 23(1):69-88. doi: 10.1007/s10552-011-9857-x
10. Rettig, E.M., D'Souza, G., Epidemiology of Head and Neck Cancer. Surg Oncol Clin N Am. 2015; 24(3):379-396. doi: 10.1016/j.soc.2015.03.001.
11. Woolgar, J., Histopathological prognosticators in oral and oropharyngeal Squamous cell carcinoma. Oral Oncol 2006; 42: 229-39.
12. Ignoffo, R.J., Rosenba, E.H., What happens in chemotherapy. In: Ko AH, Dollinger M, Rosenbaum EH, eds. Everyone's Guide to Cancer Therapy. Revised 5th Edition. Kansas City, MS: Andrew McMeel Publishing; 2008.
13. Licitra, L., Locati, L.D., Bossi, P., Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options. Ann Oncol. 2008; 7: 200-03. doi: 10.1093/annonc/mdn456.
14. Kakria, A., Rawa,t S., Bhutani, R., Gupta, G., Devnani, B., Wahi, I.K., et al., Retrospective analysis of treatment outcomes following reirradiation in locoregionally recurrent head and neck cancer patients: A single institutional study. Asia Pac J Clin Oncol. 2015; 11(2):129-34. doi: 10.1111/ajco.12261.
15. Price, K.A., Cohen, E.E., Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 2012; 13(1):35-46. doi: 10.1007/s11864-011-0176-y.
16. Kuehr, T., Thaler, J., Chemotherapy Protocols 2013-Current Protocols and "Target Therapies". Sandoz Oncology., 2013.
17. Wu, C.F., Chang, K.P., Huang, C.J., Chen, C.M., Chen, C.Y., Steve Lin, C.L., Continuous intra-arterial chemotherapy for downstaging locally advanced oral commissure carcinoma. Head Neck. 2014; 36(7):1027-33. doi: 10.1002/hed.23408.
18. Minicucci, E.M., da Silva, G.N., Salvadori, D.M., Relationship between head and neck cancer therapy and some genetic endpoints. World J Clin Oncol. 2014; 10;5(2):93-102. doi: 10.5306/wjco.v5.i2.93
19. Marvaretta, M., Stevenson, M.D., Head and Neck Cancer Treatment Protocols. Medscape., 2014. Available at: http://http://emedicine.medscape.com/article/2006216-overview
20. Argiris, A., Karamouzis, M.V., Raben, D., Ferris, R.L., Head and neck cancer. Lancet 2008; 371: 1695-1709. doi: 10.1016/S0140-6736(08)60728-X.
21. Pignon, J.P., le Maitre, A., Maillard, E., Bourhis, J., Group M-NC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14. doi: 10.1016/j.radonc.2009.04.014
22. Brockstein, B.E., Management of recurrent head and neck cancer: recent progress and future directions. Drugs 2011; 71: 1551-1559. doi: 10.2165/11592540-000000000-00000.
23. Jenkins, G., Kenneth, J., O'Byrne, K.J., Panizza, B., Richard, D.J., Genome Stability Pathways in Head and Neck Cancers. Int. J Genomics. 2013; 2013:464720. doi: 10.1155/2013/464720. Epub 2013 Nov 4.
24. Tabarestani, S., Ghafouri-Fard, S., Cancer Stem Cells and Response to Therapy. Asian Pac J Cancer Prev. 2012;13(12):5951-8.
25. Kang, H., Kiess, A., Chung, C.H., Emerging biomarkers in head and neck cancer in the era of genomics. Nature Reviews Clinical Oncology 2015: 12: 11-26. doi: 10.1038/nrclinonc.2014.192.
26. Boman, B.M., Wicha, M.S., Cancer stem cells: a step toward the cure. J Clin Oncol. 2008, 26: 2795-9. doi: 10.1200/JCO.2008.17.7436.
27. Zhou, B.B., Zhang, H., Damelin, M., Geles, K.G., Grindley, J.C., Dirks, P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009, 8(10), 806-23. doi: 10.1038/nrd2137.
28. Tabarestani, S., Ghafouri-Fard, S., Mini Rewiew: Cancer Stem Cells and Response to Therapy. Asian P. J Ca. Prev. 2012: 13.
29. Tinhofer, I., Saki, M., Niehr, F., Keilholz, U., Budach, V., Cancer stem cell characteristics of circulating tumor cells. Int J Radiat Biol. 2014; 12: 1-6. doi: 10.3109/09553002.2014.886798.
30. Chen, C., Wei, Y., Hummel, M., Hoffmann, T.K., Gross, M., Kaufmann, A.M., Albers, A.E., Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One 2011; 27;6(1). doi: 10.1371/journal.pone.0016466.
31. Prince, M.E., Sivanandan, R., Kaczorowski, A., Wolf, G.T., Kaplan, M.J., Dalerba, P., Weissman, I.L., Clarke, M.F., Ailles, L.E., Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104: 973-978.
32. Spillane, J.B., Henderson, M.A., Cancer stem cells: a review. ANZ J Surg. 2007 77(6):464-8.
33. Prince, M.E., Ailles, L.E., Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol 2008; 26: 2871-75.
34. Reiman, J.M., Knutson, K.L., Radisky, D.C., Immune Promotion of Epithelial-mesenchymal Transition and Generation of Breast Cancer Stem Cells. Cancer Res. 2010; 70: 3005-8. doi: 10.1158/0008-5472.CAN-09-4041.
35. Maugeri-Sacca, M., Vigneri, P., De Maria, R. Cancer stem cells and chemosensitivity. Clin Cancer Res 2011; 17: 4942-7. doi: 10.1158/1078-0432.CCR-10-2538
36. Bhaijee, F., Pepper, D.J., Pitman, K.T., Bell, D., Cancer stem cells in head and neck squamous cell carcinoma: a review of current knowledge and future applications. Head Neck. 2012; 34(6):894-9. doi: 10.1002/hed.21801.
37. Visus, C., Ito, D., Amoscato, A., Maciejewska-Franczak, M., Abdelsalem, A., Dhir, R., Shin, D.M., Donnenberg, V.S., Whiteside, T.L., De Leo, A.B., Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res. 2007; 67(21):10538-45.
38. Mack, B., Gires, O., CD44s and CD44v6 expression in head and neck epithelia. PLoS ONE 2008; 03(10): e3360. doi: 10.1371/journal.pone.0003360
39. Chen, Y.C., Chen, Y.W., Hsu, H.S., Tseng, L.M., Huang, P.I, Lu, K.H., Chen, D.T., Tai, L.K., Yung, M.C., Chang, S.C., Ku, H.H., Chiou, S.H., Lo, W.L., Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 2009; 385: 307-313. doi: 10.1016/j.bbrc.2009.05.048.
40. Krishnamurthy, S., Dong, Z., Vodopyanov, D., Imai, A., Helman, J.I., Prince, M.E., Wicha, M.S., Nör, J.E., Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res 2010; 70: 9969-9979. doi: 10.1158/0008-5472.CAN-10-1712.
41. Noto, Z., Yoshida, T., Okabe, M., Koike, C., Fathy, M., Tsuno, H., Tomihara, K., Arai, N., Noguchi, M., Nikaido, T., CD44 and SSEA-4 positive cells in an oral cancer cell line HSC-4 possess cancer stem-like cell characteristics. Oral Oncol. 2013; 49(8):787-95. doi: 10.1016/j.oraloncology
42. Shen, C., Xiang, M., Nie, C., Hu, H., Ma, Y., Wu, H., CD44 as a molecular marker to screen cancer stem cells in hypopharyngeal cancer. Acta Otolaryngol. 2013; 133(11):1219-26. doi: 10.3109/00016489.2013.811750.
43. Zhang, Q., Shi, S., Yen, Y., Brown, J., Ta, J.Q., Le, A.D., A subpopulation of CD133+ cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett. 2010; 28: 289(2):151-60. doi: 10.1016/j.canlet.2009.08.010.
44. Athanassiou-Papaefthymiou, M., Shkeir, O., Kim, D., Divi, V., Matossian, M., Owen, J.H., Czerwinski, M.J., Papagerakis, P., McHugh, J., Bradford, C.R., Carey, T.E., Wolf, G.T, Prince, M.E., Papagerakis, S., Evaluation of CD44 variant expression in oral, head and neck squamous cell carcinomas using a triple approach and its clinical significance. Int J Immunopathol Pharmacol. 2014; 27(3):337-49.
45. Han, J., Fujisawa, T., Husain, S.R., Puri, R.K., Identification and characterization of cancer stem cells in human head and neck squamous cell carcinoma. BMC Cancer. 2014; 11: 14:173. doi: 10.1186/1471-2407-14-173.
46. Chinn, SB., Darr, O.A., Owen, J.H., Bellile, E., McHugh, J.B., Spector, M.E., Papagerakis, S.M., Chepeha, D.B., Bradford, C.R., Carey, T.E., Prince, M.E., Cancer stem cells: Mediators of tumorigenesis and metastasis in head and neck squamous cell carcinoma. Head Neck. 2015; 37(3):317-26. doi: 10.1002/hed.23600.
47. Yanamoto, S., Yamada, S., Takahashi, H., Naruse, T., Matsushita, Y., Ikeda, H., Shiraishi, T., Seki, S., Fujita, S., Ikeda, T., Asahina, I., Umeda, M., Expression of the cancer stem cell markers CD44v6 and ABCG2 in tongue cancer: effect of neoadjuvant chemotherapy on local recurrence. Int J Oncol. 2014; 44(4):1153-62. doi: 10.3892/ijo.2014.2289.
48. Yu, C.C., Hu, F.W., Yu, C.H., Chou, M.Y., Targeting CD133 in the enhancement of chemosensitivity in oral squamous cell carcinoma-derived side population cancer stem cells. Head Neck. 2014 Dec 24. doi: 10.1002/hed.23975. [Epub ahead of print]
49. Wei, X., Wang, J., He, J., Ma, B., Chen, J., Biological characteristics of CD133(+) cancer stem cells derived from human laryngeal carcinoma cell line. Int J Clin Exp Med. 2014; 15;7(9):2453-62.
50. Zhou, C., Sun, B., The prognostic role of the cancer stem cell marker aldehyde dehydrogenase 1 in head and neck squamous cell carcinomas: A meta-analysis. Oral Oncol. 2014 50(12):1144-8. doi: 10.1016/j.oraloncology.
51. Qian, X., Wagner, S., Ma, C., Coordes, A., Gekeler, J., Klussmann, J.P., Hummel, M., Kaufmann, A.M., Albers, A.E., Prognostic significance of ALDH1A1-positive cancer stem cells in patients with locally advanced, metastasized head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2014; 140 (7):1151-8. doi: 10.1007/s00432-014-1685-4
52. Pozzi, V., Sartini, D., Rocchetti, R., Santarelli, A., Rubini, C., Morganti, S., Giuliante, R., Calabrese, S., Di Ruscio, G., Orlando, F., Provinciali, M., Saccucci, F., Lo Muzio, L., Emanuelli, M. Identification and characterization of cancer stem cells from head and neck squamous cell carcinoma cell lines. Cell Physiol Biochem. 2015; 36(2):784-98. doi: 10.1159/000430138.
53. Mannelli, G., Magnelli, L., Deganello, A., Busoni, M., Meccariello, G., Parrinello, G., Gallo, O., Detection of putative stem cells markers, CD44/CD133, in primary and lymph node metastases in head and necksquamous cell carcinomas. A preliminary immunohistochemical and in vitro study. Clin Otolaryngol. 2015; 7. doi: 10.1111/coa.12368. [Epub ahead of print]
54. Shrivastava, S., Steele, R., Sowadski, M., Crawford, S.E., Varvares, M., Ray, R.B., Identification of molecular signature of head and neck cancer stem-like cells. Sci Rep. 2015; 15: 5:7819. doi: 10.1038/srep07819.
55. Routray, S., Mohanty, N., Cancer stem cells accountability in progression of head and neck squamous cell carcinoma: the most recent trends! Mol Biol Int. 2014:375325. doi: 10.1155/2014/375325.
56. Oh, SY., Kang, H.J., Kim, Y.S., Kim, H., Lim, Y.C. CD44-negative cells in head and neck squamous carcinoma also have stem-cell like traits. Eur J Cancer. 2013; 49(1):272-80. doi: 10.1016/j.ejca.2012.06.004
57. Birzele F, Voss E, Nopora A, Honold K, Heil F, Lohmann S, Verheul H et al., CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. Clin Cancer Res. 2015;21(12):2753-62.
58. Irollo, E., Pirozzi, G., CD133: to be or not to be, is this the real question? Am J Transl Res 2013; 5 (6): 563-81.
59. Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R, Salto-Tellez M., CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol. 2010, 23(3):450-7
60. Moro M, Bertolini G, Pastorino U, Roz L, Sozzi G., Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+ Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer. J Thorac Oncol. 2015, 10(7):1027-36.
61. Yu CC, Hu FW, Yu CH, Chou MY., Targeting CD133 in the enhancement of chemosensitivity in oral squamous cell carcinoma-derived side population cancer stem cells. Head Neck. 2014 Dec 24. doi: 10.1002/hed.23975.
62. Krishnamurthy S, Dong Z, Vodopyanov D, Imai A, Helman JI, Prince ME, Wicha MS, and Nör JE., Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. 2010 Cancer Res 70, 9969-9978.
63. Nör C, Zhang Z, Warner KA, Bernardi L, Visioli F, Helman JI, Roesler R, Nör JE., Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer. Neoplasia. 2014 16(2):137-46
64. Li, Y., Ahmad, A., Sarkar and F. H., ASPP and iASPP: Implication in cancer development and progression. Cell. Mol. Biol. 2015, 61(6): 2-8.
65. Masood, N., Qureshi, M. Z. and Yasmin, A., Association of NOTCH with different microRNAs in head and neck cancer. Cell. Mol. Biol. 2015, 61(6): 9-16.
66. Amirkhah, R., Farazmand, A., Irfan-Maqsood, M., Wolkenhauerand, O. and Schmitz, U., The role of microRNAs in the resistance to colorectal cancer treatments. Cell. Mol. Biol. 2015, 61(6): 17-23.
67. Wang, Z., Chen, J. and Capobianco, A. J., The Notch signaling pathway in esophageal adenocarcinoma. Cell. Mol. Biol. 2015, 61(6): 24-32.
68. Limami, Y., Pinon, A., Riaz, A. and Simon, A., TRAIL and targeting cancer cells: between promises and obstacles. Cell. Mol. Biol. 2015, 61(6): 33-38.
69. Musella, A., Marchetti, C., Gasparri, M. L., Salerno, L., Casorelli, A., Domenici, L., Imperiale, L., Ruscito, I., Abdul Halim, T., Palaia, I., Di Donato, V., Pecorini, F., Monti, M., Muzii, L. and Panici, P. B., PARP inhibition: A promising therapeutic target in ovarian cancer. Cell. Mol. Biol. 2015, 61(6): 44-61.
70. Attar, R., Tabassum, S., Fayyaz, S., Ahmad, M. S., Nogueira, D. R., Yaylim, I., Timirci-Kahraman, O., Kucukhuseyin, O., Cacina, C., Farooqi, A. A. and Ismail, M., Natural products are the future of anticancer therapy: Preclinical and clinical advancements of Viscum album phytometabolites. Cell. Mol. Biol. 2015, 61(6): 62-68.
71. Hsu, Y-C., Hsieh, Y-H., Liao, C-C., Chong, L-W., Lee, C-Y., Yu, Y-L. and Chou, R-H., Targeting post-translational modifications of histones for cancer therapy. Cell. Mol. Biol. 2015, 61(6): 69-84.
72. Chong, L-W., Chou, R-H., Liao, C-C., Lee, T-F., Lin, Y., Yang, K-C. and Hsu, Y-C., Saturated fatty acid induces cancer stem cell-like properties in human hepatoma cells. Cell. Mol. Biol. 2015, 61(6): 85-91.
73. Smina, T. P., Mohan, A., Ayyappa, K. A., Sethuraman, S. and Krishnan, U. M., Hesperetin exerts apoptotic effect on A431 skin carcinoma cells by regulating mitogen activated protein kinases and cyclins. Cell. Mol. Biol. 2015, 61(6): 92-99.
74. Ahmadi, M., Jafari, R., Marashi, S. A. and Farazmand, A., Indirect role of microRNAs and transcription factors in the regulation of important cancer genes: A network biology approach. Cell. Mol. Biol. 2015, 61(6): 100-107.
75. Zahoor, A., Mansoor, Q., Farooqi, A. A., Fayyaz, S., Naz, G. and Ismail, M., Genetic variants in the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and death receptor (DR4) genes contribute to susceptibility to colorectal cancer in pakistani population. Cell. Mol. Biol. 2015, 61(6): 108-112.